Currently-approved PARP inhibitors carry a similar overall safety profile. Olaparib and rucaparib monotherapy treatment is most commonly associated with adverse reactions of mild or moderate severity (Common Terminology Criteria for Adverse Events grade 1 or 2) and not requiring treatment discontinuation.
The most common adverse events of any grade across the registration studies were anaemia, nausea, and fatigue or asthenia.[1,2] Fatigue or asthenia were also common with the control treatment.[1]
For more information on the safety of PARP inhibitors, click here.
References
[1] de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020 May 28;382(22):2091-2102.
[2] Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020 Nov 10;38(32):3763-3772.